Table 1.
Patient characteristic, tumour characteristic, and background variable distribution table. For continuous variables, median and interquartiles (IQ) are reported. For categorical variables, number and percentage of patients are reported. 1Proportion of study drug doses used from the target amount given the duration of intervention. 2One man from both study arms suspended the study early.
| Continuous, median (IQ) | Placebo (n = 52) | Atorvastatin (n = 56) |
|---|---|---|
| Age at recruitment, years | 64.5 (58–68) | 64.5 (59–68) |
| Intervention time, days | 27 (20.5–36) | 28 (22.5–35) |
| BMI, kg/m2 | 26.4 (24.6 – 28.7) | 26.1 (24.4 – 29.2) |
| PSA, ng/mL | 7.6 (5.8–10) | 8.4 (5.7–12) |
| %Used / Target capsules1 | 97.00 (89.7–100) | 97.64 (90–100) |
| Categorical, n (%) | ||
| Smoking | ||
| - Non smoker | 43 (84.3) | 42 (75.0) |
| - Regular smoker | 5 (9.8) | 11 (19.6) |
| - Occasional smoker | 3 (5.9) | 2 (3.6) |
| - Previous smoker | 0 (0) | 1 (1.8) |
| Pathological Gleason grade | ||
| - 5 | 1 (2.0) | 0 (0) |
| - 6 | 9 (17.7) | 12 (21.4) |
| - 7 | 35 (68.6) | 40 (71.4) |
| - 8 | 3 (5.9) | 1 (1.8) |
| - 9 | 3 (5.9) | 3 (5.4) |
| Pathological T-stage | ||
| - N/A | 1 (1.9) | 0 (0) |
| - T2a – T2c | 28 (53.8) | 30 (53.6) |
| - T3a, or higher | 23 (44.2) | 26 (46.4) |
| Diabetes | ||
| - No | 45 (88.2) | 52 (92.9) |
| - Yes | 6 (11.8) | 4 (7.1) |
| Hypertension | ||
| - No | 33 (64.7) | 35 (62.5) |
| - Yes | 18 (35.3) | 21 (37.5) |
| Completed study2 | ||
| - Yes | 51 (98.1) | 55 (98.2) |
| - No | 1 (1.9) | 1 (1.8) |
| Sex | ||
| - Male | 52 | 56 |
| Ethnicity | ||
| - Finnish | 52 | 56 |